Skip to Main Content
Welcome to theĀ Scientist.comĀ Marketplace

Go to Main Navigation



BOC Sciences

Thumbnail image


CC122 is a novel agent for DLBCL. It is an orally available pleiotropic pathway modulator. It has antitumor and immunomodulatory activity. It is used for the treatment of chronic lymphocytic leukemia. It binds CRBN and degrades Aiolos and Ikaros resulting in a mimicry of IFN signaling and apoptosis in DLBCL. It inhibits proliferation and induces apoptosis in ABC and GCB DLBCL in vitro. It was developed by Celgene Corporation(CELG) and was in clinic phase 2 trial.


  • Smiles: CC1=NC2=C(C(=CC=C2)N)C(=O)N1C3CCC(=O)NC3=O
  • Aliases: 3-(5-Amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione;CC-122; CC122; CC 122
  • Cas Number: 1015474-32-4
  • Molecular Weight: 286.29
  • Molecular Formula: C14H14N4O3